Dr. Brentjens Discusses Targets for CAR T-Cell Therapy – OncLive
OncLive |
Dr. Brentjens Discusses Targets for CAR T-Cell Therapy
OncLive Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses targets for chimeric antigen receptor (CAR) T-cell therapy. CD19 is a well-established target in B-cell cancer, with … |
